Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
Sponsor: National Cancer Institute (NCI)
ClinicalTrials ID:NCT02465060
This clinical trial is exploring how well treatments guided by genetic testing work for patients with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to previous treatments. The study aims to match patients with specific genetic changes in their cancer to targeted therapies that may be more effective for them.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The MATCH trial is a study that uses genetic testing to find specific changes in the genes of cancer cells in patients with advanced solid tumors, lymphomas, or multiple myeloma. These cancers have either spread or do not respond to standard treatments. By identifying these genetic changes, doctors can choose treatments that specifically target the cancer's unique genetic makeup, potentially improving outcomes for patients.
Description
The main goal of this study is to see how many patients respond to treatments that are specifically chosen based on the genetic changes in their cancer. The study also looks at how long patients live without their cancer getting worse and identifies other factors that might predict how well the treatment works.
Patients will first undergo genetic testing to identify specific changes in their cancer cells. Based on these results, they will be assigned to one of several treatment groups that match their genetic profile. If the initial treatment does not work or causes side effects, patients may be reassigned to a different treatment group based on further genetic testing.
Throughout the study, patients will have regular check-ups, including scans and blood tests, to monitor their health and the effectiveness of the treatment. After completing the study treatment, patients will continue to be monitored every few months to track their progress.
Eligibility Criteria
Inclusion Criteria
- Must be 18 years or older.
- Must not be pregnant or breastfeeding and must agree to use effective birth control during the study.
- Must have a confirmed diagnosis of advanced solid tumors, lymphomas, or multiple myeloma that has not responded to at least one standard treatment.
- Must have measurable disease that can be tracked during the study.
- Must be able to provide a tumor sample for genetic testing.
- Must have good overall health with a performance status of 1 or better and a life expectancy of at least 3 months.
- Must not have any serious uncontrolled medical conditions.
- Must be able to swallow pills or capsules.
- HIV-positive patients are eligible if their condition is well-controlled.
- Must have completed any prior cancer treatments at least 4 weeks before starting the study treatment.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of Alabama at Birmingham Cancer Center | 35233 | Birmingham | Alabama |
| Thomas Hospital | 36532 | Fairhope | Alabama |
| Mobile Infirmary Medical Center | 36607 | Mobile | Alabama |
| University of South Alabama Mitchell Cancer Institute | 36688 | Mobile | Alabama |
| Anchorage Associates in Radiation Medicine | 98508 | Anchorage | Alaska |
| Anchorage Radiation Therapy Center | 99504 | Anchorage | Alaska |
| Alaska Breast Care and Surgery LLC | 99508 | Anchorage | Alaska |
| Alaska Oncology and Hematology LLC | 99508 | Anchorage | Alaska |
| Alaska Regional Hospital | 99508 | Anchorage | Alaska |
| Alaska Women's Cancer Care | 99508 | Anchorage | Alaska |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.